MRS/METAvivor Metastatic Breast Cancer (MBC) Engagement Conference

Date/Time: 8AM June 22- 4:30PM June 23, 2018
Location: H. Lee Moffitt Cancer Center, Stabile Research Building, Tampa, FL

Target Audience: Stage IV metastatic breast cancer oncologists, researchers, and patients
Registration: $25, to open by February 15, 2018 at metastasis-research-conferences.org
This activity is approved for AMA PRA Category 1 Credit™ jointly provided by:

Overview:

This conference was organized by researchers of the Metastasis Research Society, patients of METAvivor, and clinicians of the Sentinel Node Oncology Foundation.

Agenda includes: clinical presentations, panel discussions, networking events, and engagement amongst all attendees in roundtable working groups.

Research priorities identified in working groups will guide MBC-related funding calls in 2018-2019 as outlined in METAvivor’s Moonshot Funding initiative approved by the NCI.

Learning Objectives

1) Describe how clinical trials, including those testing experimental therapies or the novel use of existing therapies, can be applied to the treatment of metastatic breast cancer to improve outcomes and quality of life.

2) Identify how liquid biopsy blood tests can help improve the treatment of metastatic breast cancer.

3) Explain the molecular basis of breast cancer metastasis and discuss how new targets for therapy can be applied to the treatment of metastatic breast cancer to improve outcomes.

4) Identify how to optimize personalized medical decision making based upon a metastatic breast cancer patients’ desired outcomes.

Patient travel and lodging awards available.

This conference was funded in part through a Patient-Centered Outcomes Research Institute (PCORI) Eugene Washington PCORI Engagement Award (6102-MRS).